Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states.
Study Design
- Study Type
- Case report
- Sample Size
- 1
- Population
- Single case report of a 54-year-old male experiencing maintenance insomnia, generalized anxiety, and panic symptoms associated with EPA-enriched fish oil supplement, and subsequently with montelukast (leukotriene receptor antagonist).
- Intervention
- Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states. Fish oil supplement enriched in EPA (dose not specified); also montelukast (leukotriene receptor ant
- Comparator
- No treatment
- Primary Outcome
- Anxiety, panic symptoms, and maintenance insomnia associated with EPA-enriched fish oil and montelukast
- Effect Direction
- Negative
- Risk of Bias
- High
Abstract
We recently reported a case in which a 54-year-old male experienced maintenance insomnia, generalized anxiety and panic symptoms associated with consumption of a fish oil supplement enriched in eicosapentaenoic acid (EPA). We report here that the same patient has experienced identical but more severe symptoms in response to the use of the leukotriene receptor antagonist montelukast, in accordance with other cases reported to the Food and Drug Administration. Since omega-3 fatty acids like EPA are precursors for the biosynthesis of eicosanoids including leukotrienes, a common factor to these psychiatric adverse events may be perturbations in this highly complex system of lipid inflammatory mediators.
TL;DR
It is reported that the same patient has experienced identical but more severe symptoms in response to the use of the leukotriene receptor antagonist montelukast, in accordance with other cases reported to the Food and Drug Administration.